Personalized exercise program for cancer patients

EMPOWER: Exercise and Movement to Promote Our Patients With (Gynecologic) Cancer to Enhance Resiliency

NA · University of California, San Francisco · NCT06809933

This study is testing a personalized exercise program and support group for women with gynecologic cancer to see if it helps them feel better during treatment.

Quick facts

PhaseNA
Study typeInterventional
Enrollment60 (estimated)
Ages18 Years and up
SexFemale
SponsorUniversity of California, San Francisco (other)
Drugs / interventionschemotherapy
Locations1 site (San Francisco, California)
Trial IDNCT06809933 on ClinicalTrials.gov

What this trial studies

This pilot study evaluates the feasibility and implementation of a personalized digital exercise program and virtual support group aimed at improving patient-centered outcomes for individuals undergoing treatment for gynecologic cancer. The study is conducted in two stages: the first stage assesses the feasibility and acceptability of the intervention, while the second stage involves a randomized comparison of the EMPOWER program against enhanced usual care. Participants will engage with a mobile app, health coaching, and wearable activity trackers to monitor their physical activity and overall well-being.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older who are newly diagnosed with gynecologic cancer and currently undergoing treatment.

Not a fit: Patients who are medically ineligible for exercise or have cognitive or visual impairments that limit their ability to participate may not benefit from this study.

Why it matters

Potential benefit: If successful, this program could enhance the quality of life and resilience of cancer patients during treatment.

How similar studies have performed: Other studies have shown promise in using exercise interventions for cancer patients, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 18 years or older.
2. Newly diagnosed with a gynecological cancer (including ovarian tubal or peritoneal, uterine, cervical, vaginal, vulvar, and/or gestational trophoblastic neoplasia) and currently undergoing treatment chemotherapy, surgery, etc.).
3. Able to understand study procedures and to comply with study procedures for the entire length of the study.
4. Ability to understand a written informed consent document, and the willingness to sign it.
5. Eastern Cooperative Oncology Group (ECOG) status \< 4.
6. Willingness to participate and wear an activity tracker (FitBit).
7. Planning to start systemic treatment or currently receiving Cycle 1 of systemic treatment.

Exclusion Criteria:

1. Medically ineligible or contraindications to exercise as determined by their oncologist; or contradiction to any other study-related procedure or assessment.
2. Cognitive or visual impairments that would limit participant's ability to utilize and interact with the DHT platform. Note: If a visually impaired participant has a caregiver who can help them use the DHT platform, the participant will not be excluded.
3. Existing performance of excessive physical activity (\>210 minutes per week of moderate to vigorous intensity exercise at baseline).
4. Existing enrollment in an exercise program or physical therapy program.
5. Inability to speak and read English.

Where this trial is running

San Francisco, California

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Gynecologic Cancer, Physical Activity

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.